Sign In
Buy KHTRF
$5.99
+0.0800 (+1.35%)
At Close: Jun 03, 2026
Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
06:00pm, Wednesday, 27'th May 2026
MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodi
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
06:30am, Friday, 08'th May 2026
MONTREAL, May 08, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United Medical
Knight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call Transcript
12:41pm, Thursday, 07'th May 2026
Knight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call Transcript
Knight Therapeutics Reports First Quarter 2026 Results
06:30am, Thursday, 07'th May 2026
Increased 2026 revenue guidance from $510 million to $525 million Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
04:48pm, Wednesday, 06'th May 2026
MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) pharmaceutical company, announced today the voting results from the
Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript
04:41pm, Wednesday, 06'th May 2026
Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call
07:30am, Thursday, 30'th Apr 2026
MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) pharmaceutical company, will release its first quarter 2026 financial results o
Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript
12:32pm, Thursday, 19'th Mar 2026
Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
07:30am, Thursday, 19'th Mar 2026
Delivered record-high revenues, Adjusted EBITDA 1 , Adjusted EBITDA per shar e 1 since inception Generated record high cash flow from operations since inception Provides 2026 revenues guidance of $490
Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call
07:30am, Thursday, 12'th Mar 2026
MONTREAL, March 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end
Knight Therapeutics (KHTRF) Expected to Announce Earnings on Thursday
02:24am, Thursday, 12'th Mar 2026
Knight Therapeutics (OTCMKTS:KHTRF - Get Free Report) is anticipated to release its resultson Thursday, March 19th. Analysts expect Knight Therapeutics to post earnings of ($0.0029) per share and reve
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil
07:30am, Wednesday, 18'th Feb 2026
MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Unit
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
07:30am, Thursday, 18'th Dec 2025
MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved W
Knight Therapeutics Inc. (GUD:CA) Q3 2025 Earnings Call Transcript
05:46pm, Thursday, 06'th Nov 2025
Knight Therapeutics Inc. ( GUD:CA ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Samira Sakhia - President, CEO & Director Arvind Utchanah - Chief Financial Officer Amal Kho
Knight Therapeutics Reports Third Quarter 2025 Results
07:30am, Thursday, 06'th Nov 2025
Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception Increased 2025 financial guidance
